Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

Myocardial Infarction Clinical Trial

— PATCAR  

Official title:

PATCAR Pilot Trial: A Phase 4 Study, Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00178620
• Other study ID #: PATCAR Pilot Trial HSC 03-021
• Status: Completed
• Phase: Phase 4
• Start date: September 2003
• Est. completion date: December 2009

Study information

• Verified date: August 2023
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The PATCAR study has been designed to test the hypothesis that the strategy of pre-hospital use of a "clot busting" (thrombolytic) drug followed with emergent heart catheterization including stenting of the problematic coronary artery, will result in a lower mortality and reduced repeat heart attack rates.

Early identifying and treating heart attacks patients prior to the arriving at the hospital, in those patients who qualify for the "clot busting" drugs will lower the size of the heart attack damage. This smaller heart attack will lead to fewer problems with less repeat heart attacks and death in the future.

Description:

To demonstrate feasibility of the project in a pilot trial we plan to enroll up to 500 patients to pre-hospital thrombolysis/clot busting followed by emergent catheterization and stenting of the problematic or culprit artery.

This will comprise an EMS system capable of performing pre-hospital ECGs followed by emergent transportation to a Level I Cardiovascular Center where the patients will be taken to urgent cardiac catheterization and emergent stenting of the culprit artery.

Patients identified as having typical symptoms of acute MI and an ECG consistent with acute ST elevation MI will be screened in the field by paramedics or in the spoke hospitals by the ED attending physicians using the screening form. Verbal Consent will be obtained for receiving acute therapy for their MI as outlined in the protocol. After therapy is initiated in the field or at the spoke hospital, the patients will be transported as quickly as possible to the receiving Level I Cardiovascular Center (Hub Hospital). The ED personnel in the Level I Cardiovascular Center will have activated the Interventional Cardiovascular Team and the Cath Lab personnel after having received the initial qualifying transmitted ECG.

Once the patient arrives, informed consent will be obtained by the ED investigator and/or in-house Cardiology fellow for enrollment in the PATCAR Trial. Thrombolytic ineligible patients will also be collect for this study and also go directly to the Cath Lab for PCI. Study coordinators will enter the data into the Case Report Forms and forward the completed forms to Westat-ALA for data capture in the database. In addition to the qualifying ECG, ECG's will be obtained at hospital discharge/transfer. All patients will follow the current standard of care for STEMI/heart attacks patients. Patients will have a Cardiac MRI done on day 3 or 5 of their hospital stay, to measure the size and amount of damage the heart suffered as a result of their Heart attack.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 390
• Est. completion date: December 2009
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes.

2. ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads.

3. Less than 6 hours after onset of sustained chest pain.

4. Age 18 years or older.

Exclusion Criteria:

1. Chest pain described as ripping or tearing, radiating to the back and/or down the leg, and/or systolic blood pressure > 15 mmHg difference in each arm.

2. Suspected cocaine or amphetamine use within previous 3 days.

3. Known or suspected pregnancy.

4. Cardiac arrest requiring intubation.

5. Cardiac arrest requiring greater than 20 minutes CPR.

6. Coronary intervention (PTCA/stent/CABG) within previous 4 weeks.

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Heart Disease
• Heart Diseases
• Infarction
• Myocardial Infarction

Intervention

Drug:
• Reteplase 10 Units (U) plus a second dose of reteplase 10 U
Thrombolytic-clot busting drug Retavase IV Bolus, 10 U followed by a second 10U dose
• Reteplase 10 U
Thrombolytic-clot busting drug Retavase IV Bolus in one 10U dose

Procedure:
• Urgent Percutaneous Coronary Intervention (PCI)

• Primary Percutaneous Coronary Intervention (PCI)

Locations

Country	Name	City	State
United States	Memorial Hermann Hospital / The University of Texas HSC	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality at 30 Days		30 day
Secondary	Infarction Size as Measured by Cardiac Magnetic Resonance Imaging (MRI)		1 year
Secondary	Reduction in Time From Onset of Pain to Reperfusion		1 year
Secondary	Angiographic Documentation of Reperfusion		1 year
Secondary	Electrocardiogram (ECG) ST Segment Elevation Recovery		1 year